Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]

Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]

Blog Article

Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]Martinez-Garcia MA, Miravitlles M.Int J Chron Obstruct Pulmon Dis.2017;12:1401–1411.

Page 1409, Disclosure, the text “The authors report no conflicts of interest tokidoki hello kitty blind box in this work” should read “MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharma, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants fromGlaxoSmithKline and Grifols.MAM has received speaker fees from Chiesi, Grifols, Novartis, TEVA and deus gorras Zambon; onsultancy fees from Zambon and TEVA; and research grants from Zambon”.Read the original article   .